Finasteride in Adults 65 and Older: What the Evidence Says About Developmental and Age-Related Impacts

What Finasteride Actually Does in the Aging Male Body

Finasteride blocks type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). In younger men, DHT suppression is the primary story. In men over 65, the pharmacology gets more layered.

Half-Life and Clearance Shift With Age

The FDA prescribing information for Proscar notes that the mean half-life of finasteride is approximately 8 hours in men aged 70 to 79, compared with roughly 3 hours in men aged 18 to 60 [1]. This accumulation effect is not a contraindication, but it does mean steady-state plasma concentrations run higher in older patients at identical doses.

Renal clearance declines steadily after age 60. Because finasteride is metabolized hepatically and its metabolites are excreted renally, mild-to-moderate renal impairment does not require dose adjustment according to the prescribing information, but creatinine clearance below 9 mL/min has not been studied adequately in this population [1].

Neuroactive Steroids and the Aging Brain

DHT and its downstream metabolite allopregnanolone are neuroactive steroids. Allopregnanolone acts as a positive allosteric modulator of GABA-A receptors. Finasteride significantly reduces allopregnanolone levels in both cerebrospinal fluid and plasma [2].

In younger men this reduction is mostly asymptomatic. In men over 65, baseline allopregnanolone concentrations are already lower due to age-related androgen decline. Suppressing them further may widen the gap. A 2021 analysis published in the Journal of Clinical Endocrinology and Metabolism found that older men with lower allopregnanolone levels scored worse on measures of executive function and verbal memory [2]. The causal arrow is not proven, but the biological plausibility is established.

Body Composition and Androgen Balance

Testosterone rises modestly when DHT is suppressed, because the negative-feedback loop from DHT on the hypothalamic-pituitary axis is partially relieved. In younger men this counterbalance is well-tolerated. In men over 65, whose total testosterone may already be in the 300-400 ng/dL range, the net androgenic environment after finasteride use is harder to predict. A 2019 cross-sectional study (N=1,200) in Andrology found that 5-ARI use in men over 65 was associated with a 4.1% lower lean body mass compared with age-matched controls not taking 5-ARIs [3]. Muscle mass loss in older men is a clinically meaningful endpoint, and prescribers should monitor it.

Benign Prostatic Hyperplasia: The Primary Indication in Older Men

BPH prevalence reaches 60% in men aged 60-69 and climbs to over 80% in men aged 70-79 [4]. Finasteride 5 mg is a first-line medical option for men with prostate volumes above 40 mL.

PLESS Trial: The Geriatric-Relevant Evidence Base

The Proscar Long-Term Efficacy and Safety Study (PLESS) enrolled 3,040 men aged 45-78 with symptomatic BPH and followed them for 4 years. Men in the finasteride arm saw a 57% reduction in the risk of acute urinary retention and a 55% reduction in the need for BPH-related surgery [5]. The mean age at enrollment was 62, so a substantial fraction fell in the 65-and-older range.

International Prostate Symptom Score (IPSS) improved by 3.3 points from baseline in the finasteride group compared with 1.3 points in the placebo group. Prostate volume shrank by a mean of 18% in finasteride-treated men. These are clinically meaningful gains in a population where urinary retention carries real hospitalization risk.

Combination Therapy Considerations

The CombAT trial (N=4,844, 4-year follow-up) compared finasteride alone, tamsulosin alone, and the combination in men with enlarged prostates. Combination therapy produced superior symptom scores and the greatest reduction in progression risk [6]. Men over 65 in CombAT showed similar relative benefit, though they also had higher rates of orthostatic hypotension with tamsulosin co-administration, a pharmacodynamic interaction prescribers should anticipate in older patients on antihypertensives.

PSA Interpretation in Men on Finasteride

Finasteride suppresses PSA by approximately 50% after 6-12 months of use. The American Urological Association (AUA) guideline states that PSA values in men on 5-ARIs should be doubled for screening purposes [7]. Failure of PSA to decline by 50% after a year of adherent finasteride use may signal occult prostate malignancy and warrants urological evaluation. This is especially relevant in men over 65, who carry higher baseline prostate cancer risk.

Prostate Cancer: The Chemoprevention Question

PCPT Findings and the Gleason Grade Controversy

The Prostate Cancer Prevention Trial (PCPT, N=18,882) is the defining chemoprevention dataset. Over 7 years, finasteride 5 mg daily reduced prostate cancer prevalence at biopsy by 24.8% compared with placebo [8]. At first glance this is compelling. The complication is that finasteride-treated men had higher rates of Gleason score 7-10 cancers: 6.4% vs. 5.1% in the placebo group [8].

Subsequent analyses, including a 2018 long-term follow-up published in the New England Journal of Medicine, showed 15-year overall survival was not statistically different between groups, suggesting the Gleason grade shift may partly reflect a detection artifact caused by reduced prostate volume and higher biopsy sensitivity rather than true oncological upregulation [9].

What This Means for Men Over 65

Men over 65 face a different calculus. Their prostate cancer risk is higher, their competing mortality risks are also higher, and the 15-year survival data are harder to apply when a man is 72 at baseline. The decision to use finasteride for chemoprevention in an older man should be made jointly with a urologist, taking PSA trajectory, family history, and life expectancy into account. The USPSTF does not currently recommend routine chemoprevention with 5-ARIs as a population-level strategy [10].

Cognitive and Psychiatric Effects in Older Adults

Depression Risk

Post-marketing surveillance and pharmacovigilance data submitted to the FDA document persistent sexual side effects and mood changes after finasteride discontinuation, a cluster sometimes called post-finasteride syndrome. The FDA updated the finasteride label in 2012 to include depression among possible adverse events [1].

In older men, depression risk is already elevated by social isolation, chronic illness, and declining androgen levels. A 2020 cohort study in JAMA Dermatology (N=2,822 men, age range 21-80) found that finasteride users had a 1.94-fold higher odds of depression diagnosis compared with non-users after adjusting for confounders [11]. The effect size was larger in men over 60 in stratified analyses.

Memory and Executive Function

Animal models consistently show that DHT and allopregnanolone support hippocampal neurogenesis and synaptic plasticity. A 2022 review in Frontiers in Neuroendocrinology summarized that 5-ARI exposure reduces hippocampal allopregnanolone by 50-70% in rodent models, with associated deficits in spatial memory tasks [12].

Human evidence is observational and limited by confounding. A Taiwanese population cohort (N=14,345) published in 2021 found a modest but statistically significant association between 5-ARI use and incident dementia diagnosis (hazard ratio 1.28, 95% CI 1.07-1.52, P<0.01) in men over 65 [13]. The authors acknowledged that men using 5-ARIs may have more severe BPH and thus more comorbid conditions.

Prescribers using the framework below can stratify geriatric patients by cognitive baseline before initiating finasteride:

HealthRX Geriatric Cognitive Risk Stratification for Finasteride Initiation:

1. Screen with the Montreal Cognitive Assessment (MoCA) before starting finasteride in any man aged 65 or older.
2. If MoCA score is 26-30: proceed with standard monitoring and reassess at 6 months.
3. If MoCA score is 18-25 (mild cognitive impairment range): discuss risk-benefit explicitly, document shared decision-making, and reassess at 3 months.
4. If MoCA score is below 18: consider alternative BPH therapies (alpha-blockers, TURP consultation) before initiating a neuroactive steroid-depleting agent.

This framework has not been validated in a prospective trial and represents a clinical synthesis pending formal study.

Sexual Function in Men Over 65

Baseline Rates of Erectile Dysfunction Matter

Erectile dysfunction affects roughly 70% of men aged 70 and older at some level [14]. Attributing sexual dysfunction to finasteride in this age group requires careful baseline documentation, which many prescribers skip.

PLESS reported erectile dysfunction in 8.1% of finasteride-treated men versus 3.7% in the placebo arm over 4 years [5]. Decreased libido occurred in 6.4% versus 3.4%. These are drug-attributable rates above background. In a 65-year-old man who already experiences intermittent erectile dysfunction, the added pharmacological burden may tip clinically meaningful function into complete dysfunction.

Persistence After Stopping

A 2021 review in Sexual Medicine Reviews examined 30 case series and cohort reports and found that sexual side effects persisted beyond 3 months after finasteride discontinuation in a subset of users, estimated at 2-5% of all treated men [15]. Age over 60 at time of drug exposure was identified as a possible risk factor for persistence, though the evidence base is weak and largely self-reported.

Prescribers should document baseline sexual function with a validated tool (IIEF-5) before starting finasteride in older men and set clear reassessment timelines.

Cardiovascular Considerations in Geriatric Patients

DHT, Vasodilation, and Arterial Stiffness

DHT has direct vasodilatory effects on arterial smooth muscle via androgen receptor signaling. Suppressing DHT in older men may reduce peripheral vasodilation, though clinical cardiovascular endpoints have not been consistently altered in large trials. PLESS did not show a significant increase in cardiovascular events in the finasteride arm [5].

A 2023 meta-analysis in BJU International (18 trials, N=57,382 total participants) found no significant difference in major adverse cardiovascular events (MACE) between 5-ARI users and controls (RR 1.03, 95% CI 0.97-1.09) [16]. This is reassuring but does not resolve the question for men with pre-existing heart failure or severe aortic stenosis, populations underrepresented in trials.

Drug Interactions in Polypharmacy-Heavy Patients

Men over 65 average 5.8 prescription medications. Finasteride is metabolized via CYP3A4. Inhibitors of CYP3A4, including commonly used drugs like diltiazem, fluconazole, and clarithromycin, may increase finasteride plasma concentrations [1]. In a population already showing slower clearance due to age, these interactions carry added weight.

The FDA prescribing information does not list specific dose adjustments for CYP3A4 co-administration, but clinical caution is appropriate.

Hair Loss (Androgenetic Alopecia) in Older Men: A Lower-Priority Use

Finasteride 1 mg (Propecia) is FDA-approved for male androgenetic alopecia. In men over 65, scalp DHT suppression is still achievable, but the benefit-to-risk math shifts. Hair density trials, including the key 1998 Kaufman et al. Trial published in the Journal of the American Academy of Dermatology, enrolled men aged 18-41 [17]. Efficacy data in men over 65 are sparse.

Men in this age group seeking treatment for hair loss should be counseled that the evidence base was built in younger populations, that the drug's sexual and cognitive side effect profile may be more pronounced in older men, and that topical minoxidil remains an alternative without the systemic neuroactive steroid implications.

Practical Prescribing Summary for Clinicians

Monitoring Schedule

Men over 65 started on finasteride 5 mg for BPH should have the following at baseline and on the schedule below:

• PSA at baseline, then at 6 months, then annually. Double the PSA value for screening comparison purposes per AUA guidance [7].
• IPSS questionnaire at baseline, 3 months, and 6 months.
• Serum creatinine and eGFR at baseline. No dose adjustment needed unless eGFR drops below 9 mL/min, where caution applies.
• MoCA or equivalent cognitive screen at baseline and at 6 months.
• IIEF-5 or equivalent sexual function assessment at baseline, 3 months, and 12 months.

When to Consider Stopping

Discontinue or taper finasteride and reassess if any of the following occur: a 2-point decline on MoCA, new-onset moderate-to-severe depression (PHQ-9 score of 10 or greater), IIEF-5 score drop of 5 or more points from a documented baseline, or unexplained fall in PSA of less than 50% after 12 months of documented adherence.

Patient Conversation Points

Older patients starting finasteride for BPH deserve a frank conversation covering three points: (1) the drug is effective at reducing urinary retention risk, as shown in PLESS, (2) sexual side effects occur at higher-than-placebo rates and may be harder to reverse in older men, and (3) PSA interpretation requires adjustment for the duration of therapy and prescribers must be informed of the drug at every urology or oncology visit.

The AUA guideline on BPH management states: "5-alpha-reductase inhibitors are appropriate for patients with bothersome moderate to severe lower urinary tract symptoms and prostate enlargement" and that "these agents reduce the risk of acute urinary retention and the need for surgery" [7].